Related Experiment Video
Updated: Jun 14, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
HD Therapeutics - CHDI Fifth Annual Conference
1University of Texas, Southwestern Medical Center, Departments of Pharmacology and Biochemistry, Dallas, TX 75390-9041, USA. keith.gagnon@utsouthwestern.edu
Abstract:
The CHDI Fifth Annual HD Therapeutics Conference, held in Palm Springs, CA, included topics covering new therapeutic developments in the field of Huntington's disease (HD). This conference report highlights presentations on biomarkers in HD; emerging topics in drug targeting, such as the lysosomal degradation pathway and target prediction by network-based modeling; understanding phenotype and neuronal circuit dysfunction in animal models; regulation of huntingtin protein expression and function; RNAi and antisense technology to deplete the mutant huntingtin protein; and small-molecule drugs that are progressing quickly through the clinic. Investigational drugs discussed include ALN-HTT (Alnylam Pharmaceuticals Inc/Medtronic Inc), EPI-743 (Edison Pharmaceuticals Inc), LNK-754 (Link Medicine Corp) and pridopidine (NeuroSearch A/S).
Related Concept Videos
Heart Failure VI: Adjunct Therapies
Peripheral Artery Disease III: Interprofessional Care
Therapeutic Drug Monitoring: Overview and Classification
Coronary Artery Disease V: Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
